Aromatase inhibition in elderly hypogonadal men
老年性腺功能减退男性的芳香酶抑制
基本信息
- 批准号:7265218
- 负责人:
- 金额:$ 35.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAgingAndrogensAromatase InhibitionAromatase InhibitorsBehaviorBehavioralBiochemical MarkersBiologicalBody CompositionBone DensityCardiovascular systemCessation of lifeClinicalCognitionConditionDecreased LibidoDevelopmentDisease MarkerElderlyElderly manEstradiolEstrogensFatty acid glycerol estersFeedbackFemurGoalsGonadal Steroid HormonesHealthHeart DiseasesHip region structureHormonalHyperplasiaHypogonadismHypothalamic structureImpaired cognitionInflammatoryInjuryLeadLipidsMalignant neoplasm of prostateMeasuresMediatingMediator of activation proteinMemoryMethodsMuscleOsteogenesisPhysiologicalPhysiologyPilot ProjectsPituitary GlandPlacebosPopulationPreparationPrincipal InvestigatorProductionPropertyProstateQuality of lifeQuestionnairesRandomizedRelative (related person)Replacement TherapyResearch PersonnelRiskRoleSafetySerumSex FunctioningSexualityStandards of Weights and MeasuresSymptomsTestosteroneThickTraumaUltrasonographyVertebral columnWomanX-Ray Computed Tomographyage relatedanastrozolebone lossbone metabolismcardiovascular risk factorcognitive functioncytokinedouble-blind placebo controlled trialfrailtyimprovedmalemenneurocognitive testnovelolder menosteoporosis with pathological fracturepreventprogramspsychologicradius bone structuresarcopeniaserum PSAsizesubstantia spongiosa
项目摘要
DESCRIPTION (provided by applicant): Frailty is a condition, common in the elderly, characterized by reduced strength, decreased endurance, and vulnerability to trauma. Changes in the hormonal milieu may be-an important contributor to the development of frailty as well as to other aspects of age-related physiologic decline. In men, the decline in gonadal steroid secretion may be of particular importance. Androgen replacement therapy in older men improves objective measures of frailty (e.g. body composition, strength, bone mineral density) and may improve quality of life, sexual function, and cognition as well. Androgen replacement methods are not optimal, however, and fail to separate the direct effects of androgens from the effects of estrogenic metabolites. Aromatase inhibitor administration normalizes circulating testosterone levels in hypogonadal older men while reducing estrogen levels modestly. This novel method of increasing androgen production may thus have unique physiologic properties compared to those of traditional androgen replacement. Defining these properties will allow us to clarify the relative roles of androgens and estrogens in aging male physiology. Furthermore, aromatase inhibition may prove to be a more efficacious and safer means of restoring androgen levels and preventing frailty in elderly hypogonadal men. The goal of this proposal is to assess the ability of aromatase inhibition to improve objective measures of frailty in an older hypogonadal male population via a 2-year randomized, double blind, placebo-controlled trial. Additionally, we will explore the effects of aromatase inhibition on quality of life, cognitive function, cardiovascular risk factors, and prostate-related health. With these assessments, we will better define the relative roles of estrogens and androgens in the physiology of aging and explore the mechanisms underlying gonadal steroid action in older men.
描述(由申请人提供):虚弱是一种常见于老年人的病症,其特征是力量下降、耐力下降和容易受到创伤。荷尔蒙环境的变化可能是导致虚弱以及与年龄相关的生理衰退的其他方面的重要因素。对于男性来说,性腺类固醇分泌的下降可能特别重要。老年男性的雄激素替代疗法可以改善虚弱的客观指标(例如身体成分、力量、骨矿物质密度),并可能改善生活质量、性功能和认知。然而,雄激素替代方法并不是最佳的,并且无法将雄激素的直接影响与雌激素代谢物的影响分开。芳香酶抑制剂的给药可以使性腺功能减退的老年男性的循环睾酮水平正常化,同时适度降低雌激素水平。因此,与传统雄激素替代疗法相比,这种增加雄激素产生的新方法可能具有独特的生理特性。定义这些特性将使我们能够阐明雄激素和雌激素在衰老男性生理学中的相对作用。此外,芳香酶抑制可能被证明是恢复雄激素水平和预防老年性腺功能减退男性虚弱的更有效和更安全的方法。该提案的目标是通过一项为期 2 年的随机、双盲、安慰剂对照试验,评估芳香酶抑制改善老年性腺功能减退男性人群虚弱客观指标的能力。此外,我们将探讨芳香酶抑制对生活质量、认知功能、心血管危险因素和前列腺相关健康的影响。通过这些评估,我们将更好地定义雌激素和雄激素在衰老生理学中的相对作用,并探索老年男性性腺类固醇作用的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BENJAMIN Z LEDER其他文献
BENJAMIN Z LEDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BENJAMIN Z LEDER', 18)}}的其他基金
Limited-duration anabolic therapy in postmenopausal osteoporosis
绝经后骨质疏松症的限期合成代谢治疗
- 批准号:
10782306 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Limited-duration anabolic therapy in postmenopausal osteoporosis
绝经后骨质疏松症的限期合成代谢治疗
- 批准号:
10490840 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Limited-duration anabolic therapy in postmenopausal osteoporosis
绝经后骨质疏松症的限期合成代谢治疗
- 批准号:
10295401 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Limited-duration anabolic therapy in postmenopausal osteoporosis
绝经后骨质疏松症的限期合成代谢治疗
- 批准号:
10703413 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Combination Osteoporosis Therapy and Fracture Reduction
骨质疏松症治疗和骨折复位联合治疗
- 批准号:
9770768 - 财政年份:2018
- 资助金额:
$ 35.26万 - 项目类别:
CLINICAL TRIAL: ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN
临床试验:老年性腺机能减退男性服用阿那曲唑
- 批准号:
7731249 - 财政年份:2008
- 资助金额:
$ 35.26万 - 项目类别:
ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN
老年性腺功能减退男性的阿那曲唑给药
- 批准号:
7607053 - 财政年份:2006
- 资助金额:
$ 35.26万 - 项目类别:
Aromatase inhibition in elderly hypogonadal men
老年性腺功能减退男性的芳香酶抑制
- 批准号:
7116933 - 财政年份:2005
- 资助金额:
$ 35.26万 - 项目类别:
Aromatase inhibition in elderly hypogonadal men
老年性腺功能减退男性的芳香酶抑制
- 批准号:
7473932 - 财政年份:2005
- 资助金额:
$ 35.26万 - 项目类别:
Aromatase inhibition in elderly hypogonadal men
老年性腺功能减退男性的芳香酶抑制
- 批准号:
6969400 - 财政年份:2005
- 资助金额:
$ 35.26万 - 项目类别:
相似国自然基金
ALA光动力上调炎症性成纤维细胞ZFP36抑制GADD45B/MAPK通路介导光老化皮肤组织微环境重塑的作用及机制研究
- 批准号:82303993
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
YAP1-TEAD通过转录调控同源重组修复介导皮肤光老化的作用机制
- 批准号:82371567
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
下丘脑乳头上核-海马齿状回神经环路在运动延缓认知老化中的作用及机制研究
- 批准号:82302868
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
微纳核壳结构填充体系构建及其对聚乳酸阻燃、抗老化、降解和循环的作用机制
- 批准号:52373051
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
KIAA1429介导MFAP4-m6A甲基化修饰在紫外线诱导皮肤光老化中的作用和机制研究
- 批准号:82373461
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
A Pilot Study to Evaluate the Anabolic Effect of Testosterone on Muscles of the Pelvic Floor in Older Women with Stress Urinary Incontinence
评估睾酮对患有压力性尿失禁的老年女性盆底肌肉合成代谢影响的初步研究
- 批准号:
10716432 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
Contribution of IL6 trans signaling in older females after ischemic stroke
IL6 反式信号传导在老年女性缺血性中风后的作用
- 批准号:
10660039 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
Providers and Older Pain Patients with Prescription Opioid Dependence: A Qualitative Study to Understand Barriers to Opioid Taper, Cessation, and Transition to Buprenorphine.
具有处方阿片类药物依赖性的提供者和老年疼痛患者:一项定性研究,旨在了解阿片类药物逐渐减少、戒断和过渡到丁丙诺啡的障碍。
- 批准号:
10671358 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
Steroid Hormone Pathways Regulating BPH and LUTS
调节 BPH 和 LUTS 的类固醇激素途径
- 批准号:
10601867 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别: